Collateral for a security interest recorded Jul 18, 2011 (Goldman Sachs Lending Partners LLC).
Term ended no later than Sep 4, 2026 · Medium confidence
20-year base term ended Jun 27, 2026
Filed Jun 13, 2007 as application 11/762,343 · Granted Jan 13, 2015
Base term plus 69 days of patent term adjustment (USPTO delay)
Today
Ended no later than Sep 4, 2026
2006
2026
Clock starts
Jun 27, 2006
Jun 27, 2006
Ended no later than
Sep 4, 2026
Sep 4, 2026
Granted
Jan 13, 2015
Jan 13, 2015
base term
patent term adjustment
after the term ends
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
69
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
21
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 69 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 27, 2006, when application 11/475,252, the earliest non-provisional in its chain, was filed (this one was filed Jun 13, 2007) | Jun 27, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +69 days, USPTO patent term adjustment record | Sep 4, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than Sep 4, 2026 | Medium confidence |
Partial family
| US 7,241,805 | Term ended Jun 2026 | Jun 2026 |
| US 7,569,610 | Term ended Jun 2026 | Jun 2026 |
| US 7,563,823 | Term ended Jun 2026 | Jun 2026 |
| US 7,553,992 | Term ended no later than Jun 2026 | no later than Jun 2026 |
| US 7,649,019 | Term ended no later than Jun 2026 | no later than Jun 2026 |
| US 8,932,628 | this patent no later than Sep 2026 | no later than Sep 2026 |
| Application 11/762,368 | Abandoned not computed | not computed |
| US 7,569,611 | Term ended Jun 2026 | Jun 2026 |
8 of 21 applications in this family shown, earliest filings first. Partial: 2 of the 21 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.
Assignments
The 40 most recent of 84 recorded documents are shown; the 44 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical Dutch Holdings B.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | V-Bac Holding Corp. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | VRX Holdco LLC | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1261229 B.C. Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1530065 B.C. Ltd. | Release of Security Interest |
| Nov 20, 2025 Reel 73637, frame 1 | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc.; Bausch & Lomb Incorporated; Bausch & Lomb Pharma Holdings Corp.; Commonwealth Laboratories, LLC; Dow Pharmaceutical Sciences, Inc.; Ecr Pharmaceuticals Co., Inc.; Laboratoire Chauvin S.A.S.; Medicis Pharmaceutical Corporation; Onpharma Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Solta Medical, Inc.; Synergetics USA, Inc.; Technolas Perfect Vision GmbH; Valeant Canada LP; Valeant Pharmaceuticals International; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals North America LLC; Wirra IP Pty Limited; Valeant Pharma Poland SP. Z O.O.; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 Reel 73637, frame 222 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Ireland Limited; Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Technolas Perfect Vision GmbH; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharma Poland Spolka Z Organiczona Odpowiedzialnoscia; Valeant SP. Z.O.O. | Release of Security Interest |
| Nov 20, 2025 Reel 73654, frame 300 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Bausch Health Ireland Limited; Solta Medical Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Pharma Holdings Corp. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Commonwealth Laboratories, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Dow Pharmaceutical Sciences, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Ecr Pharmaceuticals Co., Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Laboratoire Chauvin S.A.S. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Onpharma Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Synergetics USA, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Technolas Perfect Vision GmbH | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Canada LP | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals North America LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Wirra IP Pty Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland SP. Z O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Luxembourg S.A R.L. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health, Canada Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland Spolka Z Organiczona Odpowiedzialnoscia | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant SP. Z.O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical Ireland Limited | Release of Security Interest |
| Nov 25, 2025 Reel 73715, frame 375 | Bausch Health Ireland Limited | Jpmorgan Chase Bank, N.a. | U.S. Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 69 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Sep 4, 2026. We will not guess the cap.
Citations
133
later US patents cite this one
That is top 5% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.